18th week of 2022 patent applcation highlights part 12 |
Patent application number | Title | Published |
20220133821 | MONITORING AND MODIFYING THE MICROBIOME IN PATIENTS WITH RECTOVAGINAL FISTULA - Methods and materials involved in assessing and treating a mammal having a rectovaginal fistula (RVF) are provided herein. For example, the methods and materials described herein can be used for determining if a mammal having a RVF is likely to experience a successful outcome after surgical repair of the RVF, or if the mammal is likely to experience recurrence. Methods and materials for modulating the rectal and/or vaginal microbiome of mammal having a RVF also are provided herein. | 2022-05-05 |
20220133822 | NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICS - The present invention relates to a novel bacteriophage that lyses | 2022-05-05 |
20220133823 | A MODIFIED ONCOLYTIC VIRUS, COMPOSITION AND USE THEREOF - Provided is a modified oncolytic vims having a first heterologous polynucleotide encoding an immune checkpoint inhibitor and a second heterologous polynucleotide encoding an immune activator. Also provided is a pharmaceutical composition comprising the modified oncolytic virus and a method of treating a cancer comprising administering to a subject the modified oncolytic virus or the pharmaceutical composition. | 2022-05-05 |
20220133824 | ONCOLYTIC VIRUSES TARGETING STAT3 - This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers. | 2022-05-05 |
20220133825 | ONCOLYTIC VIRUSES TARGETING STAT3 - This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers. | 2022-05-05 |
20220133826 | NOVEL COMPONENT FOR CONTROLLING BIOLOGICAL FUNCTION - An object of the present invention is to prepare a novel food-derived exosome composition and to provide a cancer inhibitor or an agent for preventing decrease in tissue elasticity or an agent for improving elasticity containing a novel active ingredient. As a result of intensive studies on the purification process, the inventors have found that an exosome can be extracted from yeast mash and moromi by a unique production method. The inventors have found that the exosome recovered from the yeast mash and the moromi has a cancer cell proliferation inhibition ability, an ability to promote increase in the amount of granzyme, and an ability to promote expression of collagen and elastin. Accordingly, the inventors provide a composition for treating or preventing cancer and an agent for preventing decrease in tissue elasticity or an agent for improving elasticity, containing exosomes derived from yeast mash and moromi of sake. | 2022-05-05 |
20220133827 | HERBAL COMPOSITION FOR PREVENTING OR TREATING BENIGN PROSTATIC HYPERPLASIA DISEASE - The present invention relates to a composition for preventing or treating benign prostatic hyperplasia disease, the composition comprising, as active ingredients, extracts of | 2022-05-05 |
20220133828 | Compositions and Methods for Treating and Removing Seborrheic Keratoses - A method of diminishing the appearance of or effecting the removal or disappearance of seborrheic keratoses by the application of compositions containing a) one or more, preferably a combination of, dietary antioxidants and/or antioxidant sources, b) one or more hydrating agents and c) one or more keratolytic agents. | 2022-05-05 |
20220133829 | ANTIVIRAL COMPOSITIONS AND METHODS OF USING SAME - The present disclosure generally relates to pharmaceutical mouth rinse compositions comprising Neem oil that are useful for treating viral infections, including coronavirus infections. | 2022-05-05 |
20220133830 | TOPICAL COMPOSITION FOR CONTROL OF DEMODEX - A topical composition for treating overgrowth of Demodex mites. The topical composition preferably includes one or more active ingredients, optionally encapsulated in lipids. In example embodiments, the topical composition comprises a first active ingredient between either tea tree oil or terpinen-4-ol, and a second active ingredient of cannabidiol oil. | 2022-05-05 |
20220133831 | Sarcopoterium Spinosum Extract for Treating Inflammation - The present invention provides a | 2022-05-05 |
20220133832 | COMPOSITION FOR PREVENTING OR TREATING TINNITUS COMPRISING VITIS VINIFERA LEAF EXTRACT AS ACTIVE INGREDIENT - A composition containing a | 2022-05-05 |
20220133833 | USE OF GRAPE AND/OR SOY SUPPLEMENTS AGAINST COVID-19 AND 92 OTHER VIRUSES AND BACTERIA INCLUDING OTHER UNKNOWN VIRUSES AND BACTERIA - The invention relates to RAAS Nutritionals food functional dietary supplements derived from soybean (Glycine max), grape (vitis vinifera) and rice (Oryza sativa) for prophylaxis and therapeutic treatment of virus SARS-CoV-2, | 2022-05-05 |
20220133834 | Composition For Inhibiting Proliferation of Influenza Virus - A composition for inhibiting proliferation of influenza virus has fermented rice bran powder produced using non-pathogenic microbes that include, as cellulolytic bacteria, at least three | 2022-05-05 |
20220133835 | ANTIDIABETIC COMPOSITION COMPRISING GINGER EXTRACT OBTAINED FROM MICROWAVE-PROCESSED GINGER AND METHOD OF PREVENTING OR TREATING DIABETIS MELLITUS - Provided are a pharmaceutical composition for preventing or treating diabetes and a method of preventing or treating diabetes in a subject by using the pharmaceutical composition, the pharmaceutical composition including a ginger extract, as an active ingredient, obtained by microwave irradiation, under pressure, of ginger, an extract thereof, or a combination thereof. | 2022-05-05 |
20220133836 | PHARMACEUTICAL COMPOSITION MADE FROM HYDROPHOBIC PHYTOCHEMICALS DISPERSED IN SESAME OIL TO ENHANCE BIOACTIVITY - Pharmaceutical formulations and methods to increase the bioactivity and bioavailability of plant compound having hydrophobic phytochemicals which have poor bioavailability due to poor water solubility. Dispersions of extracts of | 2022-05-05 |
20220133837 | PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASES - Peptides and methods of use thereof, are disclosed for use in treating disorders caused by the novel coronavirus SARS-CoV-2 or resulting from COVID-19 disease, such as systemic inflammation or pneumonia. The peptides modulate the activity of the transcription factor NF κB. | 2022-05-05 |
20220133838 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2022-05-05 |
20220133839 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) - The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof. | 2022-05-05 |
20220133840 | Use of microcystin in preparation of drug for preventing or treating organ and tissue fibrosis diseases - Use of microcystins having a monocyclic heptapeptide structure in preparation of drugs for preventing or treating organ and tissue fibrosis diseases. Preferably, the microcystins are microcystin-LR with amino acids at positions 2 and 4 of a monocyclic heptapeptide structure thereof being leucine and arginine respectively, or are microcystin-RR with amino acids at positions 2 and 4 thereof being both arginine. Also provided is a method for inhibiting myofibroblast differentiation and collagen synthesis. The method is implemented by inhibiting a TGF-β/Smad signaling pathway by using one or more microcystins. | 2022-05-05 |
20220133841 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN - Embodiments of the present disclosure include methods of treating myasthenia gravis, including generalized myasthenia gravis, by providing C5 complement inhibitors. Included are devices and kits for inhibitor administration and methods of evaluating complement inhibitor treatment efficacy. | 2022-05-05 |
20220133842 | Use of fungal cyclic peptides of the destruxin type as antibacterial agents active against Clostridium perfringens - The present invention relates to the use of a destruxin or derivatives thereof to prevent or control | 2022-05-05 |
20220133843 | LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF - The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC. | 2022-05-05 |
20220133844 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF - The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof. | 2022-05-05 |
20220133845 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF - The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof. | 2022-05-05 |
20220133846 | NOVEL ANTIMICROBIAL COMPOUND AND USES THEREOF - A novel lantibiotic peptide and a composition comprising the peptide in an antimicrobial effective amount are provided. A method for preparing the composition from a medium into which host cells produce the peptide is also provided. A method of inhibiting growth of microbial cells, killing microbial cells or treating a subject infected by microbial cells, comprising administering to the microbial cells or the subject an effective amount of the peptide or the composition is further provided. Where the microbial cells are on a surface, the method may further comprise administering the peptide or the composition to the surface. | 2022-05-05 |
20220133847 | COMPOSITIONS AND METHODS FOR ALLEVIATING PAIN - A therapeutic composition includes a Ca | 2022-05-05 |
20220133848 | METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS - The disclosure relates to compositions and methods for treating a disease or condition associated with a TDP-pathology or a decline in TDP-43 functionality in neuronal cells in a subject, and for identifying candidate agents to restore expression of a normal full-length or protein coding STMN2 RNA. | 2022-05-05 |
20220133849 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SMOOTH MUSCLE DYSFUNCTION - The present disclosure provides compositions and methods to treat diseases and conditions related to smooth muscle dysfunction, or to ameliorate symptoms thereof comprising gene therapy, wherein one or more polynucleotides encoding one or more subunits of the Maxi-K channel, or mutants, variants, functional fragments, or derivatives thereof (e.g., fusions and chimaeras) are administered to a subject in need thereof, and wherein the administration of the polypeptides result in the expression of functional Maxi-K channels in the targeted smooth muscle. In some aspects, the composition of the disclosure comprise plasmid vectors containing at least one nucleic acid encoding a Maxi-K channel peptide. Also disclosed are pharmaceutical compositions, articles or manufacture, and kits. | 2022-05-05 |
20220133850 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS - Described herein are compositions and methods for treating a subject having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease or Nasu-Hakola disease. For example, using the compositions and methods of the disclosure, a subject having or at risk of developing a neurocognitive disorder may be administered one or more cells that contain a transgene encoding triggering receptor expressed on myeloid cells two (TREM2), such as a population of CD34+ hematopoietic stem or progenitor cells that express TREM2, thereby treating or preventing the disorder. | 2022-05-05 |
20220133851 | IMMUNOPOTENTIATING OR ANTICANCER ACTIVITY-AUGMENTING COMPOSITION COMPRISING MAL-EXPRESSED STEM CELL LIKE MEMORY T CELL AS ACTIVE INGREDIENT - The present invention relates to an immunopotentiating or anticancer activity-augmenting composition comprising MAL-expressed, stem cell like memory T cells as an active ingredient. According to the present invention, myelin and lymphocyte (MAL) augments the differentiation, viability, and activity of stem cell like memory cells (Tscm) and MAL-expressed Tscm can be utilized in an immunopotentiating or anticancer activity-augmenting composition. MAL can be advantageously used in a composition for cancer immunotherapy, a composition for induction of Tscm differentiation, a method for screening a cancer immunotherapy agent, a method for screening a Tscm differentiation inducing agent, etc. | 2022-05-05 |
20220133852 | RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF - A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction. | 2022-05-05 |
20220133853 | METHODS AND COMPOSITIONS FOR TREATING ULCERS - The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia. | 2022-05-05 |
20220133854 | Compositions for Treating Pathological Calcification Conditions, and Methods Using Same - The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria. | 2022-05-05 |
20220133855 | NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE - The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe. | 2022-05-05 |
20220133856 | POLYPEPTIDE CONJUGATES AND METHODS OF USES - The present disclosure provides a polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided. | 2022-05-05 |
20220133857 | ORAL FORMULATION AND TREATMENT OF PTH ANALOG - The present invention relates to method of preventing or treating disease or disorder comprising administration of oral pharmaceutical composition comprising therapeutically effective amount of PTH analog and at least one degradation preventing agent, wherein said composition provides relative bioavailability of at least 0.5%, compare to subcutaneous administration. The present invention also relates to the oral pharmaceutical composition comprising therapeutically effective amount of PTH analog and least one degradation preventing agent in physically separated dosage form and wherein said PTH analogue is in enteric coated form. At least one degradation preventing agent includes combination of at least one metal containing compound and at least one reducing agent where in at least one metal containing compound is selected for group consisting of vanadium containing compound, chromium containing compound and manganese containing compound. Preferably PTH analogue are teriparatide or abaloparatide. | 2022-05-05 |
20220133858 | PHARMACOLOGICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASE - Compositions and methods for treatment and prevention of coronavirus disease (COVID-19) and related diseases are provided. In one or more embodiments, the composition comprises two or more active ingredients selected from the group consisting of: ascorbic acid, cholecalciferol, zinc (as zinc citrate dihydrate or other forms of elemental zinc), copper (as copper gluconate or other forms of elemental copper), epigallocatechin gallate (or other flavonoids found within green tea), quercetin (as quercetin dihydrate or other forms of quercetin), hesperidin, caffeic acid, bovine lactoferrin and derivatives of the active ingredients. | 2022-05-05 |
20220133859 | ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES - The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can be used in methods designed to lower blood alcohol levels in vivo, and/or to break down the toxic byproducts of alcohol metabolism. Consequently these nanocomplexes can be used to treat a variety of conditions resulting from the consumption of alcohol, including for example, acute alcohol intoxication. | 2022-05-05 |
20220133860 | PEPTIDES FOR TREATMENT AND PREVENTION OF DIABETES AND ASSOCIATED DISORDERS - The present invention relates to peptides for the treatment of diabetes and associated disorders. | 2022-05-05 |
20220133861 | HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT EDEMA - The present disclosure provides a method of treating edema in a subject in need thereof, comprising the step of administering a composition that comprises a protein having hyaluronidase activity to a region of the subject having edema. | 2022-05-05 |
20220133862 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A. | 2022-05-05 |
20220133863 | TREATMENT OF SANFILIPPO SYNDROME TYPE B - Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety. | 2022-05-05 |
20220133864 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES - Disclosed are methods and related compositions for administering an immunoglobulin (Ig) protease in combination with synthetic nanocarriers comprising immunosuppressants. The methods and compositions provided can be used for treating Ig deposition diseases and disorders, such as IgA nephropathy. | 2022-05-05 |
20220133865 | CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE - Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals. | 2022-05-05 |
20220133866 | Method for the Treatment of a Disease Using Pigment Epithelium-Derived Factor (PEDF) - The present invention is related to a pigment epithelium-derived factor (PEDF) for use in a method for treatment and/or prevention of a disease, wherein the method comprises administering PEDF to a subject, wherein the disease is an eye disease and wherein treatment and/or prevention of the disease comprises inhibiting labyrinth capillary formation, inducing growth of choriocapillaris, tightening choriocapillaris, inhibiting extracellular matrix formation, protecting choriocapillaris, and/or guiding vessel development. | 2022-05-05 |
20220133867 | USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN - The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T. | 2022-05-05 |
20220133868 | TUMOR CELL VACCINES - The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof. | 2022-05-05 |
20220133869 | BREAST CANCER TUMOR CELL VACCINES - The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing breast cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the breast cancer vaccine compositions and methods of use thereof. | 2022-05-05 |
20220133870 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220133871 | EFFECTIVE AND EFFICIENT CONTROL OF SERUM PHOSPHATE FOR OPTIMAL BONE FORMATION - The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity. | 2022-05-05 |
20220133872 | A MONOPHOSPHORYL LIPID-A LIPOSOME BASED CANCER VACCINE - A vaccine composition for enhancing in a subject to whom the composition is administered, a production of antibodies against a disialoganglioside GD3 and/or GD2 is provided in one embodiment. The composition includes, in an embodiment, a liposome including an effective amount of disialoganglioside GD3 and/or GD2 to stimulate or enhance antibody production in the subject; and an effective amount of an adjuvant comprising monophosphory 1 lipid A (MPL). In one example, the vaccine composition may be administered to the subject in conjunction with a chemotherapy. | 2022-05-05 |
20220133873 | CANCER THERAPY - Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer. | 2022-05-05 |
20220133874 | METHODS FOR MAKING POLYSACCHARIDE-PROTEIN CONJUGATES - The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines. | 2022-05-05 |
20220133875 | METHODS FOR PREVENTING DISEASE OR DISORDER CAUSED BY RSV INFECTION - The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth. | 2022-05-05 |
20220133876 | NOVEL RECOMBINANT INFLUENZA VIRUS HAVING IMMUNE AND THERAPEUTIC RESPONSES TO HETEROLOGOUS INFLUENZA A VIRUS, AND GENETIC VECTOR AND THERAPEUTIC VACCINE COMPRISING SAME - The present disclosure relates to a novel recombinant influenza virus, in which an interferon-beta gene, which is a foreign gene associated with an antiviral action, is introduced to an NS1 gene which is an influenza virus gene that is expressed first in the host to suppress the host immune system when infected with the influenza virus, and, in contrast to existing research, the interferon-beta is separated from the NS1 protein to carry out an intrinsic function of interferon-beta of inducing an antiviral action. | 2022-05-05 |
20220133877 | Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses - The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8. | 2022-05-05 |
20220133878 | METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSV - Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×101° to about 2×10″ viral particles (vp), are described. | 2022-05-05 |
20220133879 | PORCINE EPIDEMIC DIARRHEA (PED) VIRUS VACCINE COMPOSITION AND PREPARATION METHOD THEREOF - The present invention relates to: a porcine epidemic diarrhea (PED) virus protein comprising an amino acid sequence represented by SEQ ID NO:5; a vaccine composition comprising same; and the like. | 2022-05-05 |
20220133880 | NOVEL SARS-COV-2 ANTIGENS AND USES THEREOF - The present disclosure relates to, inter alia, variants of the receptor binding domain of a coronavirus (e.g., SARS-CoV-2) having increased immunogenicity and reduced aggregation, and the use of the RBD variants in methods for preventing infection of the coronavirus. | 2022-05-05 |
20220133881 | HERPESVIRUS COMPOSITIONS AND RELATED METHODS - The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization. | 2022-05-05 |
20220133882 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME - Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications. | 2022-05-05 |
20220133883 | METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN - The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen. | 2022-05-05 |
20220133884 | COMPOUNDS USEFUL AS ADJUVANTS - The present disclosure provides heteroaryl compounds and pharmaceutically acceptable salts thereof useful as adjuvants and their use in pharmaceutical compositions such as vaccines. Further disclosed is the use of heteroaryl compounds and pharmaceutically acceptable salts thereof for stimulating an immune response in a subject. | 2022-05-05 |
20220133885 | COMPOSITIONS AND METHODS EMPLOYING ADENOSINE DEAMINASE-1 (ADA-1) AS AN ADJUVANT - Compositions and methods incorporating Adenosine deaminase-1 (ADA-1) as an adjuvant. Polynucleotides encoding novel coding sequences, polypeptides, vectors containing same, and methods of use are provided. | 2022-05-05 |
20220133886 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES - The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane. | 2022-05-05 |
20220133887 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies. | 2022-05-05 |
20220133888 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER - The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals. | 2022-05-05 |
20220133889 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 - Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders. | 2022-05-05 |
20220133890 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE - A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate. | 2022-05-05 |
20220133891 | HEMOSTATIC MICROSPHERES - Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests. | 2022-05-05 |
20220133892 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions - This disclosure relates to chimeric compounds and methods for managing neurological conditions. In certain embodiments, the compound comprises a chemical structure of a monoamine reuptake inhibitor conjugated to a chemical structure of a histone deacetylase inhibitor. In certain embodiments, this disclosure relates to methods of treating or preventing a neurological disorder, mental disorder or depression comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. | 2022-05-05 |
20220133893 | Therapeutic Nanomaterials - Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides. | 2022-05-05 |
20220133894 | BISPHOSPHONATE-LINKED COMPOUNDS - The present invention concerns novel compounds useful in the treatment of cancer, particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hydrates, and enantiomers thereof, as well as methods for their production and pharmaceutical compositions comprising them. | 2022-05-05 |
20220133895 | CAMPTOTHECIN-BASED DIMER COMPOUND, ANTICANCER DRUG AND METHOD OF ELIMINATING CANCER STEM CELL - The disclosure provides a method for removing a cancer tumor stem cell and then further removing a tumor cell and provides an application of a drug molecule and its preparation in tumor treatment or prevention. On the one hand, by inducing the death of immunogenic cells, the anti-tumor immune response is enhanced. On the other hand, indoleamine-2,3-oxygenase is inhibited, immune cells, cytokines, amino acids, etc. are regulated, which improves the niche of cancer stem cells and makes them no longer conducive to the growth of cancer stem cells. Stem cell dormancy is lifted, and the sensitivity of cancer stem cells to chemotherapy drugs and immune cells is enhanced, so that cancer stem cells and tumor cells are effectively killed, and the efficacy of tumor treatment is improved. | 2022-05-05 |
20220133896 | ANTIMICROBIAL SCAFFOLDS - Three-dimensional printed antibiotic scaffolds are provided as well as methods of use thereof and methods of making. | 2022-05-05 |
20220133897 | GLYCOCALYX MIMETIC COATINGS - Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction. | 2022-05-05 |
20220133898 | Derivatisation of Insulin with Polysaccharides - The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the protein. Typically, the polysaccharide is PSA. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2022-05-05 |
20220133899 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS - The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate. | 2022-05-05 |
20220133900 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY - Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy. | 2022-05-05 |
20220133901 | ROR1 ANTIBODY IMMUNOCONJUGATES - Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers. | 2022-05-05 |
20220133902 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy - The present application relates to a composition comprising (a) at least one immune checkpoint inhibitor and (b) at least one conjugate, wherein said conjugate is comprising (i) a target binding moiety, (ii) at least one amatoxin, and (iii) optionally at least one linker connecting said target binding moiety with said at least one amatoxin. The present application further relates to said composition for use in treating a patient having a cancer, and to a pharmaceutical formulation comprising said composition and additional excipients, as well as to methods of producing and using said composition. | 2022-05-05 |
20220133903 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS - Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject. | 2022-05-05 |
20220133904 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER - The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker comprising or having the peptide structure (shown in N->C direction) Gly-(Aax) | 2022-05-05 |
20220133905 | METHODS FOR ASSEMBLING SCAVENGING PARTICLES - The disclosure provides, methods for preparing scavenging particles, as well as methods for attaching capture agents to the particles. The disclosure further provides compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful. | 2022-05-05 |
20220133906 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TEARGETING SEQUENCE - Vectors including viral vectors comprising a genome comprising a heterologous nucleic acid encoding a lysosomal targeting sequence, fused to a lysosomal storage enzyme, enabling the lysosomal enzyme to be targeted to the lysosomes. Particular embodiments relate to a recombinant viral vector, e.g., rAAV vector encoding a lysosomal enzyme, having a lysosomal targeting IGF2(V43) sequence that binds human cation-independent mannose-6-phosphate receptor (CI-MPR) or to the IGF2 receptor, permitting proper subcellular localization of the lysosomal enzyme polypeptide to lysosomes. Also encompassed are therapeutic fusion proteins encoded by the viral vector, non-viral vectors, cells, and methods to treat a glycogen storage disease, e.g., those listed in Table 4A or Table 5A with the viral vector. t,? | 2022-05-05 |
20220133907 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO - Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo. | 2022-05-05 |
20220133908 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES - The invention relates inter alia to compositions comprising coding RNA for use in treatment of an ophthalmic disease, disorder or condition, wherein said composition is administered into the suprachoroidal space of a subject in need of treatment. Additionally, methods of treating or preventing ophthalmic diseases, disorders or conditions are provided. | 2022-05-05 |
20220133909 | HIGHLY EFFICIENT TRANSDUCTION AND LATERAL SPREAD IN THE RETINA BY A NOVEL AAV VIRUS ENHANCED BY RATIONAL DESIGN - The disclosure provides rAAV particles comprising a new capsid variant, AAV44.9(E531D). The disclosure also provides rAAV particles comprising AAV44.9(E531D) for treatment of the eye, including treatment of retinal disorders. In particular embodiments, the disclosure provides rAAV particles comprising an AAV44.9(E531D) capsid that exhibits enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. The disclosure further provides rAAV particles comprising an AAV44.9(E531D) capsid and a polynucleotide encoding a heterologous nucleic acid sequence. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided. | 2022-05-05 |
20220133910 | NEUROPROTECTION OF NEURONAL SOMA AND AXON BY MODULATING ER STRESS/UPR MOLECULES - Compositions and methods for treating a mammalian subject for an optic nerve (ON) neuropathy and/or reducing or ameliorating degeneration of axons and/or soma of RGCs are provided. Aspects of the composition include a mammalian viral vector, comprising a murine g-synuclein promoter, or functional fragment thereof, that promotes expression of a transgene specifically in retinal ganglion cells (RGCs), said promoter in operable linkage with an expression cassette encoding the transgene, wherein the expressed transgene inhibits activity of an expression product of an endogenous pro-neurodegenerative gene involved in an ER stress and/or UPR pathway that leads to axon or soma degeneration in the RGCs. Aspects of the methods include intravitreally administering the composition to treat the subject for the ON neuropathy. A variety of ON neuropathies may be treated by practicing the methods, including retinal ganglion cell degeneration, glaucoma, optic neuritis, ON traumatic injury and other ON-related diseases. | 2022-05-05 |
20220133911 | MYC, CYCLIN T1 AND/OR CDK9 FOR USE IN THE TREATMENT OF DEGENERATIVE HEART AND CNS DISORDERS - The invention relates to expression of the transcription factor Myc and/or pTEF-b and their use as medicaments for inducing proliferation in cells with limited proliferative potential, such as cardiomyocytes. Also described are methods for the prevention and treatment of diseases, such as heart disease, associated with the loss of cells or cell death. | 2022-05-05 |
20220133912 | Gene Therapy - A polynucleotide comprising a nucleotide sequence encoding methyl-CpG binding-protein 2 (MeCP2) operably linked to a strong promoter and a 3′-UTR, wherein the 3′-UTR is less than or equal to about 1000 bp in length. | 2022-05-05 |
20220133913 | SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN - Disclosed are an α | 2022-05-05 |
20220133914 | OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION - The present invention provides a photo-exothermic composite material represented by Formula (I) of CNM-(Y | 2022-05-05 |
20220133915 | HIGH YIELD PRODUCTION OF MICROBUBBLES - Microbubble production and size isolation with high yield processing. Specifically, a size isolation process is used in which a diffusion coefficient related to gas diffusion forces acting on microbubbles in suspension is controlled through maintaining diffusion parameters for the suspension. Diffusion parameters may include effective viscosity, which may be a function of microbubble volume fraction. Another diffusion parameter controlled may include temperature. In turn, microbubbles may be size isolated at high yields, which may provide for advantageous microbubble products that demonstrate increased stability for storage. | 2022-05-05 |
20220133916 | HDAC6 Inhibitors and Imaging Agents - Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided. | 2022-05-05 |
20220133918 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF - Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The compounds contain a radioactive agent which permits imaging. The compounds concentrate at sites of increased cyclooxygenase expression, such as areas of increased COX-2 expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections, assessing efficacy of diagnosis and treatment of rheumatoid arthritis, and assessing the need for treatment with opioid drugs. | 2022-05-05 |
20220133919 | ONE STEP 64Cu-BaBaSar-RGD2 PRODUCTION METHOD - A method of preparing a | 2022-05-05 |
20220133920 | METHOD AND APPARATUS FOR STERILIZING AND DISINFECTING AIR AND SURFACES AND PROTECTING A ZONE FROM EXTERNAL MICROBIAL CONTAMINATION - This invention relates to a method, process and apparatus for disinfecting and sterilizing all types of surfaces contaminated with microorganisms and toxic substances to render both inactive. Furthermore, this invention relates to both a method and apparatus for disinfecting and/or sterilizing breathable air and then using this air to protect a confined space from external contamination. The apparatus consists of a new ultra-violet (NUV) source that is more effective than mercury based 254 nm light for destroying DNA of virus, bacteria, spores and cists. It is most effective in breaking chemical bonds in toxic gases and Biotoxins that are useful to terrorists. It is combined with other apparatus that remove particulates and byproducts sometimes produced by the NUV source and maintains positive pressure of the confined space so as to prevent the influx of air from outside the protected zone. | 2022-05-05 |
20220133921 | PRODUCTION METHOD FOR HIGH-PRESSURE PROCESSED MULTILAYER STRUCTURE, AND HIGH-PRESSURE PROCESSING METHOD FOR MULTILAYER STRUCTURE - A production method for a high-pressure processed multilayer structure to be used for packages for foods and the like is provided. The production method includes: preparing a multilayer structure including an ethylene-vinyl alcohol copolymer (EVOH) layer formed from a resin composition containing an ethylene-vinyl alcohol copolymer having a saponification degree of greater than 99.7 mol % as a main component and an olefin resin layer having a thickness of less than 100 μm; and high-pressure processing the multilayer structure under a pressure of not lower than 200 MPa in an atmosphere at not lower than 20° C. | 2022-05-05 |